RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) announces that its subsidiary
BioSyent Pharma Inc. has signed a license and distribution agreement with
Notlers for Virsani(TM) personal sanitizer. The agreement grants BioSyent Pharma
the exclusive rights to manufacture, market, and distribute Virsani(TM) in
Canada and the United States. Virsani(TM) kills viruses, bacteria, and other
pathogens on hands and surfaces and is available in a convenient aerosol can
that is small enough to fit in a small purse, pocket or desk drawer making it
ideal for mobile personal hygiene. Virsani(TM) can disinfect both hands and
personal spaces like computer keyboards, telephones, common work areas, and
surfaces in fitness clubs and public washrooms.


Virsani(TM) has been approved by Health Canada and is currently available in
over 1,200 retail locations including certain Rexall PharmaPlus, Pharmasave,
International News, 7-Eleven, and Mac's Convenience stores.


"Consumer awareness of the importance of personal hygiene has been greatly
increased over the last several years as a result of outbreaks such as H1N1 flu
virus, Bird Flu, and SARS", said Rene Goehrum, CEO of BioSyent. "Virsani is a
unique, convenient product that consumers can use at home, the workplace, in
public places and when they are travelling, to provide safe and effective
sanitization when they encounter such viruses and bacteria".


BioSyent's sales and marketing activity on Virsani(TM) will commence immediately.

BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source
products that have been successfully developed and proven to be safe and
effective; manage these products through the regulatory process and product
registration (approval); and once approved, market these products in Canada.
These pharmaceuticals will compete in both the branded and generic market
segments and will not require further product development investment other than
regulatory costs.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX.


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2024 to Jul 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2023 to Jul 2024